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Abstract
Neurocognitive impairment (NCI) remains prevalent in HIV-infected subjects despite effective combination antiretroviral therapy
(CART). In subjects without evidence of hepatic decompensation, NCI is also a feature of chronic HCV infection. The present study
aimed to examine cerebral function and establish differences between HIV-HCV co-infected (HCVco) and HIV mono-infected (HIVmo)
individuals. Neurologically asymptomatic subjects with chronic HCVco were eligible and underwent computerized neurocognitive testing
(CogState; CogState Ltd, Melbourne, Australia), a dementia assessment [International HIV Dementia Scale (IHDS)] and memory assess-
ment [the Prospective and Retrospective Memory Questionnaire (PRMQ)]. Historic control data were available for 45 HIVmo individu-
als and differences between study groups were assessed. Twenty-seven HCVco subjects were recruited. Plasma HIV RNA was <50
copies/mL in 25/27 of HCVco subjects and all HIVmo subjects and nadir CD4+ cell count (mean ± SD) was 214 ± 166 cells/lL and
180 ± 130 cells/lL, in HCVco and HIVmo subjects, respectively. No statistically signiﬁcant differences in neurocognitive parameters or
PRMQ scores were observed between groups. However, a trend towards poorer executive function score was observed in HCVco
subjects (p 0.106). IHDS score (mean ± SD) was poorer in HCVco subjects (10.48 ± 1.25) vs. HIVmo subjects (11.51 ± 0.76),
(p <0.001). In a multivariate model, increasing age and HCVco were the only factors signiﬁcantly associated with poorer IHDS scores
(p 0.039 and <0.001, respectively). In HIV-infected subjects stable on CART, statistically signiﬁcantly poorer performance in the IHDS
score was observed in subjects with HCVco, although no differences were observed after neurocognitive testing or memory
assessment.
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Introduction
The outlook for individuals with chronic human-immunodeﬁ-
ciency-virus-1 (HIV) infection has been dramatically altered
ever since the advent of combination antiretroviral therapy
(CART) to that of a chronic medical condition with a life
expectancy of several decades [1]. This transformation has
been associated with comorbidities, such as hepatitis C virus
(HCV) co-infection, which became a major cause of mortality
[2].
Both chronic viral infections have similar routes of trans-
mission, resulting in 10–20% of subjects in Europe with
chronic HIV infection being co-infected with chronic HCV [3].
Such individuals are at risk of accelerated liver disease from
HCV and higher rates of CART-associated hepatotoxicity [4].
Although rates of severe HIV-associated dementia have
declined in recent years [5], minor neurocognitive impair-
ment (NCI) remains prevalent in HIV-infected subjects
despite effective antiretroviral therapy [6–8]. The character-
istics of this NCI included slowed motor function and con-
centration difﬁculties [7]. Factors associated with NCI
development remain less clear and may include the duration
of HIV infection and the degree of immune suppression sec-
ondary to HIV infection.
A similar NCI disturbance in chronic HCV infection has
been described in subjects without evidence of signiﬁcant
liver injury on liver biopsy (minimal or absent hepatitis)
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[9–11]. Several characteristics of this cerebral impairment
have been described and include depression, anxiety, fatigue
and apathy [10].
Individuals with impaired immune function secondary to
chronic HIV infection may be more susceptible to the cere-
bral effects of chronic HCV infection. However, cohort stud-
ies, although limited in numbers, have suggested similar rates
and characteristics of cerebral function abnormalities in sub-
jects chronically co-infected with both viruses compared to
those with HIV mono-infection [12–14] .
Of interest, in one series, cerebral function was noted to
improve after completion of successful viral eradication ther-
apy for chronic HCV infection [12].
In view of limited data in the ﬁeld and the increasing num-
bers of individuals living with chronic HIV and chronic HCV
co-infection, the present study aimed to investigate differ-
ences in the attributes of cerebral function test abnormali-
ties, using a comprehensive battery of tests, between HIV
and HCV co-infected (HCVco) patients and HIV mono-
infected (HIVmo) patients.
Materials and Methods
Subject selection
After receiving approval from the local human ethics com-
mittee (UK reference number: 08/H0712/15), patients
attending the Department of HIV Medicine, Imperial College
Healthcare NHS Trust, St Mary’s Hospital, London, UK,
were recruited for this study over a 6-week period (Febru-
ary 2009 to March 2009).
HCVco subjects were eligible to participate if they were
proﬁcient in English, had chronic HIV infection (HIV antibody
positive for over 6 months) and chronic HCV infection
(HCV antibody and plasma RNA positive for over 6 months).
Exclusion criteria included any active neurological disease,
dementia, current receipt of interferon and/or ribavarin
treatment for chronic HCV and current use of recreational
drugs or alcohol abuse. Subjects with evidence of hepatic
synthetic functional impairment (a serum albumin below
30 g/dL) were not eligible. A previously described control
group of HIVmo subjects were assessed; this cohort com-
prised 45 HIVmo subjects (without evidence of chronic HCV
infection) attending the same unit [15].
Study procedures
Neurocognitive testing. A computerized cognitive test battery
was applied (CogState; CogState Ltd, Melbourne, Australia),
which has been previously validated in HIV-1-infected sub-
jects [16]. Subjects underwent one full practice test prior to
the study examination to obtain optimal performance at
baseline [17]. Eight tasks in a card-game format were per-
formed that assess the cognitive domains: psychomotor func-
tion, nonverbal learning, visual and divided attention, visual
learning and memory, working memory, and executive func-
tion. Age-stratiﬁed population data were provided by the
CogState manufacturer (n = 879 healthy adults for tasks).
Memory questionnaire. A 16-item questionnaire was pre-
sented, the Prospective and Retrospective Memory Ques-
tionnaire (PRMQ) [18], in which individuals self-rate, on a
ﬁve-point scale, how often they make memory errors.
Scores can range between 16 (no memory errors) and 80
(multiple memory errors). The questionnaire takes 10 min
to complete and has high internal consistency and appropri-
ate normative population data exist [18].
International HIV Dementia Scale (IHDS). The IHDS assesses
motor speed and short-term memory based on the perfor-
mance of three tasks. These include timed ﬁnger tapping,
sequential movement and verbal recall. Scores can range
between 0 (worst performance) and 12 (best performance).
The tool has been designed as a rapid assessment to identify
subjects with HIV-related NCI and performance of a more
detailed examination is recommended in individuals with a
score of 10 or below [19].
Data analysis
Statistical analysis. Data were analysed using SPSS, version
16.0 (Chicago, IL, USA). Reaction times and accuracy scores
were generated for each computer battery task. Reaction
times were log transformed and accuracy scores were arcsine
root transformed. Linear regression modelling (or the Mann–
Whitney U-test if data were not normally distributed) were
used to investigate any associations and signiﬁcant differences
between the control group (HIVmo) and the study group
(HCVco); p <0.05 was considered statistically signiﬁcant and
parameters with p £0.10 were entered into multivariate
models. In these multivariate models, demographic factors
including patient age (years), current CD4+ count and nadir
CD4+ count (cells/lL), elapsed time since HIV diagnosis
(years), type of CART [protease inhibitor based (PI) vs. non-
nucleoside-reverse-transcriptase-inhibitor based (NNRTI)]
and the cerebrospinal ﬂuid penetration-effectiveness rank
score (CPE) [20] were investigated for associations.
Deﬁnition of neurocognitive impairment. NCI was deﬁned as a
task score more than 1 SD below the age-matched healthy
population mean, in more than two tasks using the comput-
erized NCI test [21].
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Results
Patient characteristics
Twenty-seven HCVco individuals were recruited of whom
25, with a plasma HIV viral load <50 copies/mL, were cur-
rently receiving CART.
Fifteen of the 27 subjects had a history of prior intrave-
nous drug use, but no recent intravenous drug use (within
the past 12 months). The median time subsequent to diagno-
sis of HCV infection was 4 years. Plasma HIV RNA was 113
and 6308 copies/mL, respectively, in the two subjects not
receiving CART. Baseline characteristics for the HIVmo con-
trol group and our study group are shown in Table 1.
HCVco subjects had a higher mean ± SD current CD4+
count (562 cells/lL) and nadir CD4+ count (214 cells/lL)
compared to the HIVmo group (546 ± 180 cells/lL, respec-
tively). The mean number of years subsequent to HIV diag-
nosis was slightly higher in the HCVco group (14.41 years
vs.12.2 years). Groups were well matched for the type of
CART (PI vs. NNRTI-based therapy).
The mean serum alanine aminotransferase level in the
HCVco group was 109 IU (range 15–269 IU) and the mean
serum albumin was 44 g/dL (range 31–50 g/dL).
Neurocognitive test, PRMQ and IHDS results
The results of the study assessments are shown in Table 2.
Statistically signiﬁcantly poorer IHDS scores were observed
in HCVco subjects compared to HIVmo subjects with
mean ± SD scores of 10.48 ± 1.25 vs. 11.51 ± 0.76, respec-
tively (p <0.001). Interestingly, a greater number of subjects
had an IHDS score below or equal to 10 (i.e. the suggested
cut-off score for the IHDS) [19] in the HCVco group (nine
of 27; 33%) compared to the HIVmo group (one of 45; 2%).
No other statistically signiﬁcant differences between the
study groups were observed, including differences in working
memory, a domain previously reported to be impaired in
chronic HCV infection [22] (working memory domain was
>1 SD below population mean in 11% of subjects in both
study groups). However, a trend towards poorer executive
function performance (dimensional shift) was observed in the
HCVco group (mean number of errors 17.9 vs. 15.0 in
HCVco vs. HIVmo groups, respectively; p 0.106, r = 0.192).
A trend was observed towards improved PRMQ scores in
the HCVco group (p 0.112). Asymptomatic NCI was present
in three of 27 (11%) and ten of 45 (22%) of subjects in the
HCVco and HIVmo groups, respectively (p 0.241).
In a multivariate model (Table 3), poorer IHDS score was
statistically signiﬁcantly associated with increasing age (p
0.039, 95% CI )0.46 to )0.01) and HCVco group (p <0.001,
95% CI )1.54 to )0.62) only.
Discussion
We have observed signiﬁcantly poorer IHDS scores and a
trend toward poorer executive function performance on
neurocognitive testing in subjects with HCVco compared to
subjects with HIVmo. Despite using a sophisticated psycho-
metric battery, we did not observe any statistically signiﬁcant
differences in neurocognitive function between our study
groups.
The IHDS is a validated tool utilized to screen for NCI in
HIV infection [19,23]. To our knowledge, this tool has not
been utilized in HCV-co-infected individuals. The IHDS incor-
porates both ﬁne motor testing and verbal recall. The incor-
poration of both these testing modalities within the one
assessment may have lead to a greater power to detect dif-
ferences between our two study groups compared to the
other testing modalities applied in this project, which focused
on a single cognitive domain. For example, with the cognitive
testing battery we have utilized, a trend toward a difference
between the study groups was observed concerning execu-
tive functioning. The lack of an observation of a statistically
signiﬁcant difference between groups may be secondary to
the lack of incorporating cognitive domains together.
The well described extra-hepatic sequelae of chronic HCV
mono-infection have been associated with a series of
cerebral manifestations, including the identiﬁcation of the
TABLE 1. Baseline characteristics of the patients studied
Baseline characteristics Overall HCVco HIVmo
Number, n 72 27 45
Gender (male/female), n 60/12 22/5 38/7
Current CD4+ (cells/lL) 552 (276) 562 (290) 546 (271)
Nadir CD4+ (cells/lL) 193 (145) 214 (166) 180 (129)
Years since HIV diagnosis 13 (5.7) 14 (5.1) 12 (6.0)
Age (years) 47 (10) 46 (8) 48 (11)
Number on antiretroviral
therapy, n (%)
70 (97) 25 (93) 45 (100)
% NNRTI based 44% 44% 44%
% PI based 56% 56% 56%
CPE score 1.67 (0.62) 1.52 (0.47) 1.76 (0.68)
Education, number years 14 (2.7)
Alanine aminotransferase (IU) 109 (66)
Albumin (g/dL) 44 (4.2)
HCV genotype, n
1a 9
2 1
3 2
Most recent HCV PCR,
copies/mL
2 926 102
(5.55 · 106)
Data are the mean ± SD unless otherwise stated.
HCVco, HIV-HCV co-infected; HIVmo, HIV mono-infected; NNRTI, non-nucleo-
side reverse transcriptase inhibitor-based antiretroviral therapy; PI, protease
inhibitor-based antiretroviral therapy; CPE, cerebrospinal penetration-effective-
ness rank score.
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hepatitis C virus in the central nervous system [24–26] and
abnormalities in neurocognitive function testing in the
absence of signiﬁcant liver disease [10,27,28]. Impairment of
cognitive function has also been described in subjects co-
infected with chronic HIV and HCV co-infection [13,29–31].
Ryan et al. [13] have previously reported impaired executive
function in subjects with HIV and chronic HCV co-infection,
as observed in the present study. Although this observation
in our cohort did not reach statistical signiﬁcance, a trend
toward poorer function in the HCVco group was observed
(p 0.106, r = 0.192). However, relatively small numbers in
our study groups may have limited the power to detect such
differences. Of note, improvements in executive function
testing have been described both in HIV mono-infected sub-
jects after commencing CART [32] and in HCV co-infected
subjects [12] after successful anti-HCV treatment. Because
the type of CART was similar in both study groups, our
observations of poorer cognitive function in the HCVco
group are likely to be secondary to the presence of hepatitis
C viraemia, rather than to any speciﬁc differences in anti-HIV
therapies between the study groups.
In a recently reported, large series recruiting 517 subjects,
no differences in neurocognitive function were observed in
HIV-infected subjects, stable on CART with suppressed HIV
plasma viraemia, with (n = 172) and without (n = 345) evi-
dence of chronic hepatitis C co-infection [14]. Neurocogni-
tive testing in this study was relatively simple and only
included trailmaking tests, an intelligence scale and the digit
symbol test.
Although our study comprised fewer patients (a total of
72), a series of much more detailed neurocognitive tests
were performed, allowing signiﬁcant differences between the
study groups to be observed. The comprehensive testing
battery applied in the study included assessment of verbal
recall within the IHDS score and a measure of executive
processing function within the computerized neurocognitive
TABLE 2. Results of neurocognitive testing, International HIV Dementia Scale (IHDS) and Prospective and Retrospective
Memory Questionnaire (PRMQ) scores in both study groups
Task Task measure
Traditional neurocognitive
domain
Test results
Comparison between
study groups
Overall HIVmo HCVco p-value 95% CI r-value
Neurocognitive testing results (computer battery)
Associative learning Accuracy Nonverbal learning 0.82 (0.17) 0.84 (0.17) 0.80 (0.16) 0.349 )0.119 to 0.042 0.112
Detection Speed Psychomotor function 2.53 (0.11) 2.53 (0.12) 2.52 (0.11) 0.677 )0.067 to 0.044 0.050
Identiﬁcation Speed Attention 2.71 (0.08) 2.71 (0.08) 2.71 (0.08) 0.829 )0.034 to 0.042 0.260
Matching Speed Attention 2.85 (0.85) 2.85 (0.87) 2.85 (0.85) 0.798 )0.036 to 0.047 0.310
Monitoring Speed Divided attention 2.63 (0.11) 2.64 (0.12) 2.60 (0.92) 0.179 )0.091 to 0.017 0.160
One card learning Accuracy Learning 0.78 (0.14) 0.77 (0.16) 0.79 (0.10) 0.527 )0.047 to 0.091 0.760
One back memory Speed Working memory – simple 2.87 (0.10) 2.87 (0.10) 2.87 (0.11) 0.980 )0.048 to 0.049 0.002
One back memory Accuracy Working memory – simple 1.29 (0.23) 1.27 (0.23) 1.32 (0.22) 0.331 )0.057 to 0.165 0.116
Dimensional shift Errors Executive function 16.06 (7.45) 14.96 (6.09) 17.89 (9.12) 0.106 )0.641 to 6.508 0.192
Visual discrimination Errors Executive function 3.99 (2.82) 4.13 (3.17) 3.74 (2.14) 0.571 )1.769 to 0.984 0.068
IHDS Score – 11.12 (1.09) 11.51 (0.76) 10.48 (1.25) <0.001 – –
PRMQ Score – 40 (10.24) 41.49 (10.49) 37.52 (9.50) 0.112 )8.889 to 0.948 –
Neurocognitive impairment Number (%) – 13 (18%) 10 (22%) 3 (11%) 0.241 )0.299 to 0.076 –
Speed – log10 milliseconds (SD); accuracy – arcsine transformation of the square root of proportion of correct responses (SD); errors – total number errors (SD); HCVco,
HIV-HCV co-infected; HIVmo, HIV mono-infected; IHDS, International HIV Dementia Scale; PRMQ, Prospective and Retrospective Memory Questionnaire.
p <0.10 are shown in bold.
TABLE 3. Multivariate analysis: factors with p-value <0.10 in univariate model
Parameter Univariate analysis Multivariate analysis
IHDS score p-value 95% CI r-value p-value 95% CI
Age, per 10 year increase 0.155 )0.434 to 0.071 0.169 0.039 )0.458 to )0.012
Current CD4+ count, per 100 cell/uL increase 0.081 )0.174 to 0.010 0.208 0.067 )0.160 to 0.06
Nadir CD4+ count, per 100 cell/uL increase 0.375 )0.266 to 0.101 0.109 – –
PRMQ score 0.808 )0.022 to 0.028 0.029 – –
CPE score 0.255 )0.179 to 0.662 0.139 – –
Years since HIV diagnosis 0.286 )0.068 to 0.021 0.127 – –
NNRTI based therapy 0.976 )0.530 to 0.514 0.004 – –
PI based therapy 0.712 )0.622 to 0.427 0.045 – –
HCVco Group <0.001 )1.501 to )0.558 0.462 <0.001 )1.542 to )0.617
HCVco, HIV-HCV co-infected; IHDS, International HIV Dementia Scale; PRMQ, prospective and retrospective memory questionnaire; CPE, cerebrospinal penetration-effec-
tiveness rank score; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
p <0.05 shown in bold.
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assessment. Such assessments allowed differences between
the study groups to be observed, where less comprehensive
testing may have otherwise been un-illuminating.
Differences existed between the baseline characteristics of
our study groups which may be of relevance to our ﬁndings.
Current and nadir CD4+ lymphocyte counts were higher in
the HCVco group. Because both study groups were
recruited from the same HIV out-patient clinic, these differ-
ences may reﬂect differences in clinical practice. Cohort
studies have suggested that subjects with HCVco may have
more rapid HIV and HCV disease progression [4]. Clinicians
should be aware of these data and manage such patients
more aggressively, initiating CART at an earlier stage of HIV
disease. NCI has been reported to be related to chronic
immune suppression and stage of HIV disease [33].
By virtue of an earlier initiation of CART in the HCVco
group, we may not have observed other potential differences
that may have arisen between the study groups if CART had
been commenced at the same CD4+ lymphocyte count.
The present study has some other limitations. NCI has
been more frequently observed in female subjects with
chronic HCV infection, both in subjects with and without
HIV co-infection [31].
Very few female subjects were recruited in the present
study, limiting the power to assess the possible effects of
gender on cerebral function testing. Furthermore, no assess-
ment of depression was undertaken. Rates of depression
may be increased in HCV infection [34], and depression may
be associated with impaired cerebral function [35].
Of note, substance misuse is associated with abnormal
results with respect to cerebral function testing [36] in
cohorts similar to the group that we studied, and it has been
associated with the presence of HCV RNA in cerebrospinal
ﬂuid [37]. Subjects with an active history of substance misuse
were excluded from the present study. However, this was
based on direct patient questioning, rather than laboratory
techniques to exclude recent drug misuse.
These data add to the literature exploring the cerebral
effect of chronic HCV infection in different disease areas,
highlighting that differences in cerebral function are observed
in HIV-infected subjects despite effective viral-suppressive
therapy for HIV-disease.
The data obtained in the present study highlight several
areas of importance for future research. First, research aim-
ing to explore potential improvements in cerebral function
testing after successful antiviral treatment for chronic HCV
infection is justiﬁed, both in subjects with chronic HCV
mono-infection and in other disease states such as HIV
co-infection. Second, comprehensive cognitive testing batter-
ies comprise essential tools that allow the cerebral effects of
chronic HCV infection to be observed. Such testing batteries
must assess several cognitive domains but need not be oner-
ously time-consuming. The comprehensive battery that we
have utilized assessed several cognitive domains but only
took approximately 40 min in total to complete when admin-
istered by experienced study staff.
Acknowledgements
We are grateful for support from the NIHR Biomedical
Research Centre funding scheme. We would like to thank T.
Chenhall (CogState Ltd, Melbourne, Australia) for advice
regarding the analysis of the neurocognitive test results.
Transparency Declaration
P. Maruff works for CogState Ltd. No other authors have
any other conﬂict of interest.
References
1. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-
infected patients: a collaborative analysis of 18 HIV cohort studies.
Lancet 2009; 373: 1352–1363.
2. Qurishi N, Kreuzberg C, Luchters G, Effenberger W, Kupfer B,
Sauerbruch T et al. Effect of antiretroviral therapy on liver-related
mortality in patients with HIV and hepatitis C virus coinfection.
Lancet 2003; 9397: 1708–1713.
3. Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A
et al. Inﬂuence of hepatitis C virus infection on HIV-1 disease pro-
gression and response to highly active antiretroviral therapy. J Infect
Dis 2005; 192: 992–1002.
4. Mocroft A, Phillips AN, Soriano V, Rockstroh J, Blaxhult A, Katlama
C et al. Reasons for stopping antiretrovirals used in an initial highly
active antiretroviral regimen: increased incidence of stopping due to
toxicity or patient/physician choice in patients with hepatitis C coin-
fection. AIDS Res Hum Retroviruses 2005; 21: 743–752.
5. d’Arminio Monforte A, Cinque P, Mocroft A, Goebel FD, Antunes F,
Katlama C et al. Changing incidence of central nervous system dis-
eases in the EuroSIDA cohort. Ann Neurol 2004; 55: 320–328.
6. Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ. Changes
to AIDS dementia complex in the era of highly active antiretroviral
therapy. Aids 1999; 13: 1249–1253.
7. Tozzi V, Balestra P, Bellagamba R, Corpolongo A, Salvatori MF,
Visco-Comandini U et al. Persistence of neuropsychologic deﬁcits
despite long-term highly active antiretroviral therapy in patients with
HIV-related neurocognitive impairment: prevalence and risk factors.
J Acquir Immune Deﬁc Syndr 2007; 45: 174–182.
8. Larussa D, Lorenzini P, Cingolani A, Bossolasco S, Grisetti S, Bongio-
vanni M et al. Highly active antiretroviral therapy reduces the
age-associated risk of dementia in a cohort of older HIV-1-infected
patients. AIDS Res Hum Retroviruses 2006; 22: 386–392.
9. Jamal MM, Soni A, Quinn PG, Wheeler DE, Arora S, Johnston DE.
Clinical features of hepatitis C-infected patients with persistently
CMI Thiyagarajan et al. Cerebral function test in HIV-infected subjects 1583
ª2010 The Authors
Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 1579–1584
normal alanine transaminase levels in the Southwestern United
States. Hepatology 1999; 30: 1307–1311.
10. Forton DM, Allsop JM, Main J, Foster GR, Thomas HC, Taylor-Robin-
son SD. Evidence for a cerebral effect of the hepatitis C virus. Lancet
2001; 358: 38–39.
11. Hilsabeck RC, Perry W, Hassanein Tl. Neuropsychological impair-
ment in patients with chronic hepatitis C. Hepatology 2002; 35: 440–
446.
12. Thein HH, Maruff P, Krahn MD, Kaldor JM, Koorey DJ, Brew BJ et al.
Improved cognitive function as a consequence of hepatitis C virus
treatment. HIV Med 2007; 8: 520–528.
13. Ryan EL, Morgello S, Isaacs K, Naseer M, Gerits P. Neuropsychiatric
impact of hepatitis C on advanced HIV. Neurology 2004; 62: 957–962.
14. Clifford DB, Smurzynski M, Park LS, Yeh TM, Zhao Y, Blair L et al.
Effects of active HCV replication on neurologic status in HIV RNA
virally suppressed patients. Neurology 2009; 73: 309–314.
15. Garvey LJ, Yerrakalva D, Winston A. Correlations between compu-
terized battery testing and a memory questionnaire for identiﬁcation
of neurocognitive impairment in HIV type 1-infected subjects on
stable antiretroviral therapy. AIDS Res Hum Retroviruses 2009; 25:
765–769.
16. Cysique LA, Maruff P, Darby D, Brew BJ. The assessment of cognitive
function in advanced HIV-1 infection and AIDS dementia complex
using a new computerised cognitive test battery. Arch Clin Neuro-
psychol 2006; 21: 185–194.
17. Collie A, Maruff P, Darby DG, McStephen M. The effects of practice
on the cognitive test performance of neurologically normal individuals
assessed at brief test-retest intervals. J Int Neuropsychol Soc 2003; 9:
419–428.
18. Crawford JR, Smith G, Maylor EA, Della Sala S, Logie RH. The Pro-
spective and Retrospective Memory Questionnaire (PRMQ): Norma-
tive data and latent structure in a large non-clinical sample. Memory
2003; 11: 261–275.
19. Sacktor NC, Wong M, Nakasujja N, Skolasky RL, Selnes OA, Musisi
S et al. The International HIV Dementia Scale: a new rapid screening
test for HIV dementia. Aids 2005; 19: 1367–1374.
20. Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier
AC et al. Validation of the CNS Penetration-Effectiveness rank for
quantifying antiretroviral penetration into the central nervous system.
Arch Neurol 2008; 65: 65–70.
21. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M
et al. Updated research nosology for HIV-associated neurocognitive
disorders. Neurology 2007; 69: 1789–1799.
22. Forton DM, Thomas HC, Murphy CA, Allsop JM, Foster GR, Main J
et al. Hepatitis C and cognitive impairment in a cohort of patients
with mild liver disease. Hepatology 2002; 35: 433–439.
23. Njamnshi AK, Djientcheu Vde P, Fonsah JY, Yepnjio FN, Njamnshi
DM, Muna WE. The International HIV Dementia Scale is a useful
screening tool for HIV-associated dementia/cognitive impairment in
HIV-infected adults in Yaounde-Cameroon. J Acquir Immune Deﬁc
Syndr 2008; 49: 393–397.
24. Bagaglio S, Cinque P, Racca S, Pedale R, Grasso MA, Lazzarin A et al.
Hepatitis C virus populations in the plasma, peripheral blood mono-
nuclear cells and cerebrospinal ﬂuid of HIV/hepatitis C virus-co-
infected patients. Aids 2005; 19(Suppl 3): S151–S165.
25. Forton DM, Karayiannis P, Mahmud N, Taylor-Robinson SD, Thomas
HC. Identiﬁcation of unique hepatitis C virus quasispecies in the cen-
tral nervous system and comparative analysis of internal translational
efﬁciency of brain, liver, and serum variants. J Virol 2004; 78: 5170–
5183.
26. Fishman SL, Murray JM, Eng FJ, Walewski JL, Morgello S, Branch AD.
Molecular and bioinformatic evidence of hepatitis C virus evolution in
brain. J Infect Dis 2008; 197: 597–607.
27. Weissenborn K, Krause J, Bokemeyer M, Hecker H, Schuler A,
Ennen JC et al. Hepatitis C virus infection affects the brain-evidence
from psychometric studies and magnetic resonance spectroscopy.
J Hepatol 2004; 41: 845–851.
28. McAndrews MP, Farcnik K, Carlen P, Damyanovich A, Mrkonjic M,
Jones S et al. Prevalence and signiﬁcance of neurocognitive dysfunc-
tion in hepatitis C in the absence of correlated risk factors. Hepatol-
ogy 2005; 41: 801–808.
29. Hinkin CH, Castellon SA, Levine AJ, Barclay TR, Singer EJ. Neurocog-
nition in individuals co-infected with HIV and hepatitis C. J Addict Dis
2008; 27: 11–17.
30. Parsons TD, Tucker KA, Hall CD, Robertson WT, Eron JJ, Fried
MW et al. Neurocognitive functioning and HAART in HIV and hepati-
tis C virus co-infection. Aids 2006; 20: 1591–1595.
31. Richardson JL, Nowicki M, Danley K, Martin EM, Cohen MH, Gonza-
lez R et al. Neuropsychological functioning in a cohort of HIV- and
hepatitis C virus-infected women. Aids 2005; 19: 1659–1667.
32. Cysique LA, Vaida F, Letendre S, Gibson S, Cherner M, Woods SP et
al. Dynamics of cognitive change in impaired HIV-positive patients
initiating antiretroviral therapy. Neurology. 2009 May 27.
33. Marcondes MC, Flynn C, Huitron-Rezendiz S, Watry DD, Zandonatti
M, Fox HS. Early antiretroviral treatment prevents the development
of central nervous system abnormalities in simian immunodeﬁciency
virus-infected rhesus monkeys. Aids 2009; 23: 1187–1195.
34. Libman H, Saitz R, Nunes D, Cheng DM, Richardson JM, Vidaver J
et al. Hepatitis C infection is associated with depressive symptoms in
HIV-infected adults with alcohol problems. Am J Gastroenterol 2006;
101: 1804–1810.
35. Marvel CL, Paradiso S. Cognitive and neurological impairment in
mood disorders. Psychiatr Clin North Am 2004; 27: 19–36, vii-viii.
36. Martin-Thormeyer EM, Paul RH. Drug abuse and hepatitis c infection
as comorbid features of hiv associated neurocognitive disorder:
neurocognitive and neuroimaging features. Neuropsychol Rev 2009; 19:
215–231.
37. Letendre S, Paulino AD, Rockenstein E, Adame A, Crews L, Cherner
M et al. Pathogenesis of hepatitis C virus coinfection in the brains of
patients infected with HIV. J Infect Dis 2007; 196: 361–370.
1584 Clinical Microbiology and Infection, Volume 16 Number 10, October 2010 CMI
ª2010 The Authors
Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 1579–1584
